- Home
- CWD vs AIDX Comparison
CWD vs AIDX Comparison
Compare CWD & AIDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CWD | AIDX |
|---|---|---|
| Founded | 2009 | N/A |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Real Estate | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 9.2M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | CWD | AIDX |
|---|---|---|
| Price | $0.61 | $0.59 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 82.4K | ★ 317.0K |
| Earning Date | 05-14-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $20,097,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $19.17 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.60 | $0.54 |
| 52 Week High | $46.21 | $14.09 |
Technical Indicators
Market Signals| Indicator | CWD | AIDX |
|---|---|---|
| Relative Strength Index (RSI) | 26.06 | 32.32 |
| Support Level | N/A | $0.54 |
| Resistance Level | $1.13 | $1.00 |
| Average True Range (ATR) | 0.07 | 0.10 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 3.62 | 10.89 |
Price Performance
Historical ComparisonAbout CWD CaliberCos Inc.
CaliberCos Inc is an asset management firm whose primary goal is to enhance the wealth of investors seeking to make investments in middle-market assets. The company's funds include investment vehicles focused on real estate, private equity, and debt facilities. The company earns asset management fees calculated as a percentage of managed capital in funds and offerings. The company markets services through direct sales to private investors, wholesaling to investment advisers, direct sales to family offices and institutions and through in-house client services. The company operates into three reportable segments: Fund Management, Development, and Brokerage. The majority of revenue is derived from the fund management fees segment.
About AIDX 20/20 Biolabs Inc. Common Stock
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.